ClinicalTrials.gov
public full text
Public Domain
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evidence of RB94 expression within tumor tissue after systemic administration of SGT-94.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors#1009079
- Study of PBF-999 in Solid Tumour Advanced Cancer#874081
- A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients#810668
- A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.#1138221
- Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors#970033
Record · ID 1059913
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive